NPS 2390Group I mGlu antagonist CAS# 226878-01-9 |
2D Structure
- NPS-2143
Catalog No.:BCC4409
CAS No.:284035-33-2
- Calcium-Sensing Receptor Antagonists I
Catalog No.:BCC1448
CAS No.:478963-79-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 226878-01-9 | SDF | Download SDF |
PubChem ID | 7067728 | Appearance | Powder |
Formula | C19H21N3O | M.Wt | 307.39 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in DMSO and to 50 mM in ethanol | ||
Chemical Name | N-(1-adamantyl)quinoxaline-2-carboxamide | ||
SMILES | C1C2CC3CC1CC(C2)(C3)NC(=O)C4=NC5=CC=CC=C5N=C4 | ||
Standard InChIKey | ZKFVOZCCAXQXBU-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H21N3O/c23-18(17-11-20-15-3-1-2-4-16(15)21-17)22-19-8-12-5-13(9-19)7-14(6-12)10-19/h1-4,11-14H,5-10H2,(H,22,23) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Group I mGlu antagonist; displays noncompetitive antagonist activity at both mGlu1 and mGlu5 receptors. Thought to act on a site separate from the glutamate binding pocket. |
NPS 2390 Dilution Calculator
NPS 2390 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.2532 mL | 16.266 mL | 32.532 mL | 65.0639 mL | 81.3299 mL |
5 mM | 0.6506 mL | 3.2532 mL | 6.5064 mL | 13.0128 mL | 16.266 mL |
10 mM | 0.3253 mL | 1.6266 mL | 3.2532 mL | 6.5064 mL | 8.133 mL |
50 mM | 0.0651 mL | 0.3253 mL | 0.6506 mL | 1.3013 mL | 1.6266 mL |
100 mM | 0.0325 mL | 0.1627 mL | 0.3253 mL | 0.6506 mL | 0.8133 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2-(3,4-dihydroxyphenyl)-2-hydroxypropanoic acid
Catalog No.:BCN6296
CAS No.:22681-72-7
- Bakkenolide Db
Catalog No.:BCN7117
CAS No.:226711-23-5
- Fosamprenavir Calcium Salt
Catalog No.:BCC1581
CAS No.:226700-81-8
- 3-Hydroxy-12-oleanene-23,28-dioic acid
Catalog No.:BCN1482
CAS No.:226562-47-6
- Amaronol B
Catalog No.:BCN5071
CAS No.:226561-02-0
- Amaronol A
Catalog No.:BCN5070
CAS No.:226560-96-9
- 4,6,7-Trihydroxycoumarin
Catalog No.:BCC9203
CAS No.:22649-24-7
- Torachrysone
Catalog No.:BCN5069
CAS No.:22649-04-3
- Cinacalcet
Catalog No.:BCC1483
CAS No.:226256-56-0
- Methyl kulonate
Catalog No.:BCN7952
CAS No.:22611-37-6
- Kulactone
Catalog No.:BCN7953
CAS No.:22611-36-5
- Demethoxycurcumin
Catalog No.:BCN5974
CAS No.:22608-11-3
- Kaempferol-3-beta-O-glucuronide
Catalog No.:BCN2503
CAS No.:22688-78-4
- Quercetin-3-O-glucuronide
Catalog No.:BCN3149
CAS No.:22688-79-5
- Lansoprazole sodium
Catalog No.:BCC4298
CAS No.:226904-00-3
- 4-Hydroxy-1,10-secocadin-5-ene-1,10-dione
Catalog No.:BCN6661
CAS No.:226904-40-1
- LB42708
Catalog No.:BCC5344
CAS No.:226929-39-1
- Emapunil
Catalog No.:BCC5521
CAS No.:226954-04-7
- 3,6-Dimethoxyapigenin
Catalog No.:BCN4830
CAS No.:22697-65-0
- Hyponine E
Catalog No.:BCC8999
CAS No.:226975-99-1
- 9-Deacetyl-9-benzoyl-10-debenzoyl-4beta,20-epoxytaxchinin A
Catalog No.:BCN7676
CAS No.:227011-48-5
- AZ 11645373
Catalog No.:BCC7646
CAS No.:227088-94-0
- (3S,7S)-5,6-Dehydro-4''-de-O-methylcentrolobine
Catalog No.:BCN1481
CAS No.:227289-51-2
- Mucrolidin
Catalog No.:BCN5072
CAS No.:227471-20-7
Effects of calcium-sensing receptors on apoptosis in rat hippocampus during hypoxia/reoxygenation through the ERK1/2 pathway.[Pubmed:26617793]
Int J Clin Exp Pathol. 2015 Sep 1;8(9):10808-15. eCollection 2015.
OBJECTIVES: To explore the effects of calcium-sensing receptors (CaSR) on apoptosis in rat hippocampus during hypoxia/reoxygenation (H/R). METHODS: After rat hippocampus was isolated, the cultures were subjected to H/R, and meanwhile gadolinium chloride (GdCl3, agonist of CaSR) and NPS 2390 (antagonists of CaSR) were added to reperfusion solution. The number of hippocampal neuron, cell viability and apoptosis rate were determined by inverted microscope, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) and flow cytometer (FCM), respectively. Besides, caspase-3, Bax, cytochrome C (Cyt-c), extracellular signal-regulated protein kinase (ERK) 1/2, pERK1/2, P38 and pP38 were analyzed by Western blotting. RESULTS: The hippocampal neuron number and cell viability were significantly decreased during H/R, and were further significantly reduced when co-treatment with CaSR agonist GdCl3. But the effects of GdCl3 were attenuated by NPS-2390. Whereas, apoptosis rate, the expression level of caspase-3, Bax and Cyt-c were all significantly increased under H/R condition, and was further significantly increased by GdCl3, but were reversed by NPS-2390 (P < 0.05). Moreover, there were no significant differences in expression of ERK1/2, P38 and pP38 among different groups. However, the expression of pERK1/2 was significantly increased during H/R, but was significantly reduced by NPS 2390 (P < 0.05). CONCLUSION: The results suggest that CaSR might play significant roles in the induction of hippocampus apoptosis in rat during H/R through phosphorylation of ERK1/2.
Effects of calcium-sensing receptors on apoptosis in rat hippocampus during hypoxia/re-oxygenation through the ERK1/2 pathway.[Pubmed:26550201]
Int J Clin Exp Med. 2015 Aug 15;8(8):12858-65. eCollection 2015.
OBJECTIVES: To explore the effects of calcium-sensing receptors (CaSR) on apoptosis in rat hippocampus during hypoxia/re-oxygenation (H/R). METHODS: After post-culturing of isolated rat hippocampus, the cultures were subjected to H/R, meanwhile gadolinium chloride (GdCl3, agonist of CaSR) and NPS 2390 (antagonists of CaSR) was added to reperfusion solution. The number of hippocampal neuron, cell proliferation assay and apoptosis rate was determined by inverted microscope, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) and flow cytometer (FCM). Besides, caspase-3, Bax, cytochrome C (Cyt-c), extracellular signal-regulated protein kinase (ERK) 1/2, pERK1/2, P38 and pP38 were analyzed by western blotting. RESULTS: The hippocampal neuron number and cell viability were significantly decreased after H/R treatment, and were further significantly reduced when co-treatment with CaSR agonist GdCl3. But the effects of GdCl3 were attenuated by NPS-2390. Whereas, apoptosis rate, the expression level of caspase-3, Bax and Cyt-c were all significantly increased under H/R condition, and was further significantly increased by GdCl3, but were reversed by NPS-2390 (P < 0.05). Moreover, there were no significant differences in expression of ERK1/2, P38 and pP38 among different groups. However, the expression of pERK1/2 was significantly increased after H/R treatment, but was significantly reduced by NPS 2390 (P < 0.05). CONCLUSION: The results suggest that CaSR might play significant roles in the induction of hippocampus apoptosis in rat during H/R through phosphorylation of ERK1/2.
Calcium-sensing receptor in rat vagal bronchopulmonary sensory neurons regulates the function of the capsaicin receptor TRPV1.[Pubmed:23913765]
Exp Physiol. 2013 Nov;98(11):1631-42.
Extracellular calcium-sensing receptor (CaSR) has been known to play a critical role in the maintainance of systemic Ca(2+) homeostasis. Recent studies have shown that CaSR is also expressed in many tissues that are not directly related to plasma Ca(2+) regulation, such as the central and peripheral nervous system, where the function of this receptor remains to be defined. In this study, we aimed to investigate the expression of CaSR and its potential interaction with transient receptor potential vanilloid receptor type 1 (TRPV1) in rat vagal bronchopulmonary sensory neurons. Our immunohistochemical experiments demonstrated the expression of CaSR in these sensory neurons as well as in trachea and lung parenchyma. Results from our whole-cell patch-clamp recordings in isolated neurons showed that strong activation of CaSR with high concentrations of its agonists, including spermine, NPS R-568 and Ca(2+), inhibited the capsaicin-evoked whole-cell inward current. Blockade of CaSR with its antagonists NPS 2390 and NPS 2143 significantly enhanced the capsaicin-evoked TRPV1 current. These data suggest that CaSR is likely to be involved in the integration of primary bronchopulmonary sensory inputs in physiological and/or pathophysiological conditions.
Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists.[Pubmed:15771457]
J Med Chem. 2005 Mar 24;48(6):2134-53.
We describe the discovery and the structure-activity relationship of a new series of quinoline derivatives acting as selective and highly potent noncompetitive mGlu1 antagonists. We first identified cis-10 as a fairly potent mGlu1 antagonist (IC(50) = 20 nM) in a cell-based signal transduction assay on the rat mGlu1 receptor expressed in CHO-K1 cells, and then we were able to design and synthesize highly potent compounds on both rat and human mGlu1 receptors as exemplified by compound cis-64a, which has an antagonist potency of 0.5 nM for the human mGlu1 receptor. We briefly present and discuss the in vitro metabolic stability of the compounds in human liver microsomes. We finally report the pharmacokinetic properties of our lead compound cis-64a.
[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists.[Pubmed:12695537]
Mol Pharmacol. 2003 May;63(5):1082-93.
R214127 was shown to be a potent and noncompetitive metabotropic glutamate 1 (mGlu1) receptor-selective antagonist. The kinetics and pharmacology of [(3)H]1-(3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-2-phenyl-1-ethanone (R214127) binding to rat mGlu1a receptor Chinese hamster ovary (CHO)-dhfr(-) membranes was investigated, as well as the distribution of [(3)H]R214127 binding in rat brain tissue and sections. Specific binding to rat mGlu1a receptor CHO-dhfr(-) membranes was approximately 92% of total and was optimal at 4 degrees C. Full association was reached within 5 min, and [(3)H]R214127 bound to a single binding site with an apparent K(D) of 0.90 +/- 0.14 nM and a B(max) of 6512 +/- 1501 fmol/mg of protein. Inhibition experiments showed that [(3)H]R214127 binding was completely blocked by 2-quinoxaline-carboxamide-N-adamantan-1-yl (NPS 2390), (3aS,6aS)-6a-naphtalan-2-ylmethyl-5-methyliden-hexahydro-cyclopenta[c]furan-1-on (BAY 36-7620), and 7-(hydroxyimino)cyclo-propa[b]chromen-1a-carboxylate ethyl ester (CPCCOEt), but was not displaced by competitive mGlu1 receptor ligands such as glutamate and quisqualate, suggesting that R214127, NPS 2390, BAY 36-7620, and CPCCOEt bind to the same site or mutually exclusive sites. Experiments using rat cortex, striatum, hippocampus and cerebellum revealed that [(3)H]R214127 labeled a single high-affinity binding site (K(D) approximately 1 nM). B(max) values were highest in the cerebellum (4302 +/- 2042 fmol/mg of protein) and were 741 +/- 48, 688 +/- 125, and 471 +/- 68 fmol/mg of protein in the striatum, hippocampus, and cortex, respectively. The distribution of [(3)H]R214127 binding in rat brain was investigated in more detail by radioligand autoradiography. A high density of binding sites was detected in the molecular layer of the cerebellum. Moderate labeling was seen in the CA3 and dentate gyrus of the hippocampus, thalamus, olfactory tubercle, amygdala, and substantia nigra reticulata. The cerebral cortex, caudate putamen, ventral pallidum, and nucleus accumbens showed lower labeling. The high affinity and selectivity of [(3)H]R214127 for mGlu1 receptors renders this compound the ligand of choice to study the native mGlu1 receptor in brain.